Scaffold Based Search on the Desferithiocin Archetype.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Toxicology

Background:

• Iron overload disorders necessitate orally available iron chelators with improved safety and efficacy.
• Desferrithiocin (DFT), an orally available iron chelator, exhibits favorable pharmacokinetics but is limited by nephrotoxicity.
• DFT's chemical structure is optimized for iron chelation but also contributes to its toxicity.

Purpose of the Study:

• To review and classify Desferrithiocin (DFT) analogues developed to overcome nephrotoxicity.
• To discuss the structure-activity relationships (SAR) of these DFT analogues.
• To provide insights into developing novel, non-nephrotoxic iron chelators.

Main Methods:

• Classification of DFT analogues into pyridine and phenyl classes based on structural modifications.
• Subdivision based on the presence and number of hydroxyl functional groups.
• Analysis of structure-activity relationships concerning iron clearance and toxicity.

Main Results:

• DFT analogues have been systematically modified at the pyridine and thiazoline rings.
• Compounds are categorized based on core structure (pyridine vs. phenyl) and hydroxylation patterns.
• Structure-activity relationship studies guide the development of analogues with reduced nephrotoxicity.

Conclusions:

• Developing non-nephrotoxic Desferrithiocin (DFT) analogues is crucial for treating iron overload.
• Understanding SAR is key to designing safer and effective iron chelating agents.
• Further research into novel DFT analogues holds promise for improved therapeutic options.